Arcellx, Inc.

Arcellx, Inc. is a clinical-stage biotechnology company specializing in the development of immunotherapies for cancer and other incurable diseases. The company's lead product candidate, CART-ddBCMA, is in phase 1 clinical trial for treating relapsed or refractory multiple myeloma. Additionally, Arcellx is developing ACLX-001, an immunotherapeutic combination targeting BCMA for the treatment of multiple myeloma, as well as ACLX-002 and ACLX-003 for r/r acute myeloid leukemia and myelodysplastic syndrome. The company also has solid tumor programs in its pipeline.

Products

• CART-ddBCMA for multiple myeloma

• ACLX-001 for multiple myeloma

• ACLX-002 and ACLX-003 for acute myeloid leukemia and myelodysplastic syndrome